尼莫利祖马布作为无情系统性巨细胞瘤的替代治疗选择
Sezim Minbaeva1, Stephen K Tyring2
1Department of Dermatology, Texas Tech University Health Sciences Center School of Medicine, Lubbock, USA.
Cureus
|February 9, 2026
概括
当其他疗法失败时,尼莫利祖马布为惰性全身性巨细胞瘤 (ISM) 提供了一种新的治疗选择. 这种生物有效地解决了对多种治疗耐药的患者的严重.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 惰性系统性乳腺细胞瘤 (ISM) 是一种慢性乳腺细胞疾病.
- 像和疹这样的症状可能对标准治疗不耐药.
- 对于不耐受或不适合AVAPRITINIB等向治疗的患者,存在有限的选择.
研究的目的:
- 评估尼莫利祖马布在耐火性ISM患者中的疗效.
- 探索尼莫利祖马布作为一种替代疗法,当KIT抑制是不可行的.
主要方法:
- 一个62岁的女性,有11年的ISM病史,接受了Nemolizumab.
- 治疗包括60毫克的加重剂量,然后每四周增加30毫克.
- 患者之前多次治疗失败,包括生物药物,并拒绝了avapritinib.
主要成果:
- 在服用12剂尼莫利祖马布后,的完全消失.
- 患者经历了显著的症状缓解.
结论:
- 尼莫利祖马布可能是耐火性ISM的可行的治疗选择.
- 它为那些不适合AVAPRITINIB的患者提供了潜在的治疗途径.
相关概念视频
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
203
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
203
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
189
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
189
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
178
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
178
Alternative RNA Splicing
25.2K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
25.2K
Alternative RNA Splicing
5.2K
5.2K
Null and Alternative Hypotheses
12.8K
The actual hypothesis testing begins by considering two hypotheses. They are termed the null hypothesis and the alternative hypothesis. These hypotheses contain opposing viewpoints.
The null hypothesis, denoted by H0 is a statement of no difference between the variables—they are not related. This can often be considered the status quo. As a result if you cannot accept the null, it requires some action.
The alternative hypothesis, denoted by H1 or Ha, is a claim about the...
The null hypothesis, denoted by H0 is a statement of no difference between the variables—they are not related. This can often be considered the status quo. As a result if you cannot accept the null, it requires some action.
The alternative hypothesis, denoted by H1 or Ha, is a claim about the...
12.8K


